Ken Griffin
PHAT icon

Ken Griffin’s Phathom Pharmaceuticals PHAT Stock Holding History

Ken Griffin’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.26M Buy
383,058
+71,743
+23% +$906K ﹤0.01% 4606
2025
Q4 		$5.16M Sell
311,315
-197,405
-39% -$2.82M ﹤0.01% 4241
2025
Q3 		$5.99M Buy
+508,720
New +$5.25M ﹤0.01% 4031
2025
Q2 		– Sell
-179,721
Closed -$994K – 14460
2025
Q1 		$1.13M Buy
179,721
+107,714
+150% +$654K ﹤0.01% 6702
2024
Q4 		$585K Sell
72,007
-148,396
-67% -$1.84M ﹤0.01% 8215
2024
Q3 		$3.98M Buy
220,403
+141,587
+180% +$1.98M ﹤0.01% 4317
2024
Q2 		$812K Sell
78,816
-46,829
-37% -$482K ﹤0.01% 7013
2024
Q1 		$1.33M Buy
125,645
+114,112
+989% +$969K ﹤0.01% 6336
2023
Q4 		$105K Sell
11,533
-264,194
-96% -$2.28M ﹤0.01% 10868
2023
Q3 		$2.86M Buy
275,727
+258,812
+1,530% +$3.55M ﹤0.01% 4562
2023
Q2 		$242K Sell
16,915
-171,569
-91% -$1.98M ﹤0.01% 9476
2023
Q1 		$1.35M Buy
188,484
+186,731
+10,652% +$1.64M ﹤0.01% 6144
2022
Q4 		$19.7K Buy
+1,753
New +$18.1K ﹤0.01% 13156
2022
Q3 		– Sell
-25,012
Closed -$238K – 13349
2022
Q2 		$212K Buy
+25,012
New +$257K ﹤0.01% 10583
2022
Q1 		– Sell
-11,466
Closed -$185K – 14337
2021
Q4 		$226K Sell
11,466
-7,944
-41% -$187K ﹤0.01% 11599
2021
Q3 		$623K Sell
19,410
-60,964
-76% -$2.03M ﹤0.01% 9337
2021
Q2 		$2.72M Buy
80,374
+71,833
+841% +$2.57M ﹤0.01% 5845
2021
Q1 		$321K Sell
8,541
-3,535
-29% -$148K ﹤0.01% 10698
2020
Q4 		$401K Buy
12,076
+5,360
+80% +$217K ﹤0.01% 8565
2020
Q3 		$246K Buy
+6,716
New +$233K ﹤0.01% 8467
2020
Q2 		– Sell
-11,948
Closed -$308K – 10326
2020
Q1 		$308K Buy
+11,948
New +$399K ﹤0.01% 7296

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Ken Griffin's PHAT Position: Q1 2026 in Review

Ken Griffin increased its Phathom Pharmaceuticals (PHAT) stake by 23% in Q1 2026, buying an estimated $906K and bringing the position to 383,058 shares worth $4.26M. The position accounts for ﹤0.01% of the portfolio, ranked #4606.

Ken Griffin first reported a position in PHAT in Q1 2020 and has held it in 21 quarters since. The position peaked at $5.99M in Q3 2025. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • Ken Griffin held 383,058 shares of Phathom Pharmaceuticals worth $4.26M as of Q1 2026.
  • Ken Griffin bought 71,743 Phathom Pharmaceuticals shares in Q1 2026, an estimated $906K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #4606 holding.
  • Ken Griffin first reported a position in Phathom Pharmaceuticals in Q1 2020 and has held it in 21 quarters since.
  • Ken Griffin's Phathom Pharmaceuticals position peaked at $5.99M in Q3 2025.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.